Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 883-890

  Congdon, Lauren M ^a,c   Pourpak, Alan ^b,c   Escalante, Aluvia M ^c   Dorr, Robert T ^b,c   Landowski, Terry H ^b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Combination therapy; Multiple myeloma; Proteasome inhibition; Topoisomerase II

Indexed keywords

6 ETHOXYAZONAFIDE; AMP 53; ANTHRACENE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOUBLE STRANDED DNA; DOXORUBICIN; ETHONAFIDE; MITOX; MITOXANTRONE; POISON; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; ISOQUINOLINES; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES;

EID: 38649122066     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.026     Document Type: Article

References (26)

1. Richardson P.G., Schlossman R., Hideshima T., and Anderson K.C. New treatments for multiple myeloma. Oncology (Williston Park) 19 14 (2005) 1781-1792
2. Kellner U., Sehested M., Jensen P.B., Gieseler F., and Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 3 4 (2002) 235-243
3. Kaufmann S.H., Gore S.D., Miller C.B., Jones R.J., Zwelling L.A., Schneider E., et al. Topoisomerase II and the response to antileukemic therapy. Leuk Lymphoma 29 3-4 (1998) 217-237
4. Ju B.G., Lunyak V.V., Perissi V., Garcia-Bassets I., Rose D.W., Glass C.K., et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 312 5781 (2006) 1798-1802
5. Walker J.V., and Nitiss J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 20 4 (2002) 570-589
6. Sun J., He Z.G., Cheng G., Wang S.J., Hao X.H., and Zou M.J. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10 1 (2004) RA5-RA14
7. Grabowski D.R., Dubyak G.R., Rybicki L., Hidaka H., and Ganapathi R. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes. Biochem Pharmacol 56 3 (1998) 345-349
8. Prost S. Mechanisms of resistance to topoisomerases poisons. Gen Pharmacol 26 8 (1995) 1773-1784
9. Dalton W.S., Durie B.G.M., Alberts D.S., Gerlach J.H., and Cress A.E. Characterization of a new drug resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46 (1986) 5125-5130
10. Futscher B.W., Foley N.E., Gleason-Guzman M.C., Meltzer P.S., Sullivan D.M., and Dalton W.S. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66 (1996) 520-525
11. Montecucco A., and Biamonti G. Cellular response to etoposide treatment. Cancer Lett (2006)
12. Zhang A., Lyu Y.L., Lin C.P., Zhou N., Azarova A.M., Wood L.M., et al. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem 281 47 (2006) 35997-36003
13. Salmena L., Lam V., McPherson J.P., and Goldenberg G.J. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression. Biochem Pharmacol 61 7 (2001) 795-802
14. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82 2 (2002) 373-428
15. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4 5 (2004) 349-360
16. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 29 Suppl. 1 (2003) 33-9-33-39
17. Adams J., Behnke M., Chen S., Cruickshank A.A., Dick L.R., Grenier L., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8 4 (1998) 333-338
18. Blade J., Cibeira M.T., and Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 44 5 (2005) 440-448
19. San Miguel J., Blade J., Boccadoro M., Cavenagh J., Glasmacher A., Jagannath S., et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11 1 (2006) 51-61
20. Dorr R.T., Liddil J.D., Sami S.M., Remers W., Hersh E.M., and Alberts D.S. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs 12 3 (2001) 213-220
21. Pourpak A., Landowski T.H., and Dorr R. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther (2007)
22. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., and Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110 5 (2002) 563-574
23. Landowski T.H., Gleason-Guzman M.C., and Dalton W.S. Selection for drug resistance results in resistance to Fas mediated apoptosis. Blood 89 (1997) 1180-1187
24. Landowski T.H., Olashaw N.E., Agrawal D., and Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22 16 (2003) 2417-2421
25. Barker C.R., McNamara A.V., Rackstraw S.A., Nelson D.E., White M.R., Watson A.J., et al. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res 34 4 (2006) 1148-1157
26. Biehn S.E., Moore D.T., Voorhees P.M., Garcia R.A., Lehman M.J., Dees E.C., et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86 3 (2007) 211-216